Logo Lanfrica
  • Accueil
  • Atlas
  • Analyses
  • Documentation
  • Sign in

© 2026 Lanfrica. Tous droits réservés. Tous les droits d'auteur des ressources affichées sur le site Web Lanfrica appartiennent aux détenteurs de droits d'auteur d'origine, sauf indication contraire explicite.

Genetic dynamics of HIV-1 : recombination, drug resistance and intrahost evolution

Domaine:

healthcare

Type de record:

paper
Créateur:
Kar
Hôte:avatar

A striking characteristic of HIV is the enormous capacity of genetic variation. Frequent mutations, deletions, insertions and recombination events create a population of genetically related but non-identical viruses that is under constant change and ready to adapt to environmental changes. The great genetic variability allows the virus to escape the host immune system, develop drug resistance and escape candidate vaccines. Therefore, knowledge about the genetic variation of HIV-1 is important for the design of drugs and vaccines, and for the understanding of the natural history and pathogenesis of the infection. In this thesis, the genetic dynamics of HIV-1 was investigated from different perspectives with special focus on recombination, drug resistance and intra-host evolution.

A new pyrosequencing assay was developed that could rapidly screen for the presence of drug resistance mutations in the protease gene of HIV-1. The method was robust and sensitive compared to conventional sequencing. Further development of the assay may provide a new tool for efficient monitoring of the development of drug resistance mutations in HIV-1 patients.

The prevalence of drug resistance mutations in HIV-1 from newly diagnosed Swedish patients was investigated by sequencing of the protease and RT genes. Among 100 patient samples, 6 carried mutations that conferred intermediate to strong drug resistance, indicating transmission of drug-resistant virus from antiviral treated patients. In addition, subtype-specific amino acid patterns were found that might be important to consider when patients infected with different subtypes are treated. Several intersubtype recombinant HIV-1 genomes originating from Central and West Africa were characterised by full-length sequencing and recombination analysis. Two genomes were the first representatives of a new circulating recombinant form called CRF13-cpx, and two other genomes belonged to CRF11-cpx. Several unique recombinant genomes were identified as well as two other isolates that may represent an additional new CRF.

The problems associated with the characterisation of complex recombinant genomes resulted in the development of a new metric called the branching index . The branching index can aid in the classification of problematic sequence fragments that show only distant relationship to a subtype despite a high bootstrap value. We believe that this new approach may be a useful tool for classification of complicated HIV-1 sequences. The intrahost evolution of HIV-1 was investigated by sequencing the env gene of an HIV-1 population in sequential samples from an asymptomatic drug-naive patient. Phylogenetic analysis of the sequence clones revealed a robust pattern of subpopulations. In addition, it was possible to distinguish a directed evolution from the intrasample diversity at a time interval of only two weeks. Calculations of nucleotide substitution rates indicated an underestimation of the genetic divergence at longer time intervals, suggesting that current nucleotide substitution models need to be improved.

List of scientific papers

I. OMeara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J (2001). Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J Clin Microbiol. 39(2): 464-73.
https://pubmed.ncbi.nlm.nih…

II. Maljkovic I, Wilbe K, Solver E, Alaeus A, Leitner T (2003). Limited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01_AE. AIDS Res Hum Retroviruses. 19(11): 989-97.
https://pubmed.ncbi.nlm.nih…

III. Wilbe K, Casper C, Albert J, Leitner T (2002). Identification of two CRF11-cpx genomes and two preliminary representatives of a new circulating recombinant form (CRF13-cpx) of HIV type 1 in Cameroon. AIDS Res Hum Retroviruses. 18(12): 849-56.
https://pubmed.ncbi.nlm.nih…

IV. Wilbe K, Salminen M, Laukkanen T, McCutchan F, Ray SC, Albert J, Leitner T (2003). Characterization of novel recombinant HIV-1 genomes using the branching index. Virology. 316(1): 116-25.
https://pubmed.ncbi.nlm.nih…

V. Wilbe K, Alaeus A, Albert J, Leitner T (2004). Detailed genetic analysis of an evolving HIV-1 population. [Manuscript]

Visit

figshare.com

Tags

Thesis

Licenses

All rights reserved

Similaires

HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in NigeriaILRI-Genomics-Platform/SARS-CoV-2-intrahost-genetic-evolution: v1.0.0Genetic diversity, transmission dynamics and drug resistance of Mycobacterium tuberculosis in AngolaEvolution of HIV-1 Drug Resistance after Virological Failure of First-line Antiretroviral Therapy in Lusaka, ZambiaDrug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in MauritaniaGenetic Diversity and Drug Resistance Mutations in HIV type 1 from Untreated Patients in Bamako, Mali

HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria

Objective: This study was designed to provide information on the genetic diversity of

ILRI-Genomics-Platform/SARS-CoV-2-intrahost-genetic-evolution: v1.0.0

Analysis code for assessment of SARS-CoV-2 genetic evolution in Kenya

Genetic diversity, transmission dynamics and drug resistance of Mycobacterium tuberculosis in Angola

Abstract Tuberculosis (TB) poses a serious public health problem in Angola. No surveillance data on

Evolution of HIV-1 Drug Resistance after Virological Failure of First-line Antiretroviral Therapy in Lusaka, Zambia

Background HIV viral load (VL) and resistance testing are limited in sub-Sahar

Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania

Abstract The aim of this cross‐sectional study was to evaluate the drug resistance mutationprofil

Genetic Diversity and Drug Resistance Mutations in HIV type 1 from Untreated Patients in Bamako, Mali

Objective To determine the genetic diversity of HIV-1 reverse transcriptase (R